JX Partners

JX Partners is a South Korean venture capital firm established in October 2016, specializing in investments across early, mid, and Pre-IPO stages. The firm primarily targets technology-driven companies, aiming for co-growth with its portfolio companies. Their investment strategy is centered on identifying promising small and medium-sized venture enterprises with significant growth potential.

Founded in October 2016, JX Partners was established as a startup investment company. The firm's operations are led by CEO Koo Ja-deuk, who is also a major shareholder alongside FR Tech, a listed company. JX Partners was created with the vision of building a mutually beneficial partnership among limited partners, portfolio companies, and the management company, fostering a virtuous cycle of investment and growth.

JX Partners has built a diverse portfolio with a strong emphasis on deep technology, biotechnology, healthcare, and advanced IT. Notable investments include Polaris 3D, an autonomous driving robot manufacturer; Shaperon, a developer of therapies for various diseases; and Noeul, a company focused on global blood diagnostics. The firm has also invested in companies like AItrics (AI-powered clinical decision support), Nextgen Bioscience, Mezoo (monitoring equipment), Ereon (hardware), XL Games (game development), INNOSPACE (space technology), Novelty Nobility (therapeutics), PharmAbcine (monoclonal antibodies), Curocell (immune cell therapies), and Specx (space and aerospace deep-tech). Several of their portfolio companies, such as Shaperon, INNOSPACE, and PharmAbcine, have successfully achieved IPOs.

The team at JX Partners leverages differentiated investment experience and expertise to identify and nurture promising ventures. Under the leadership of CEO Koo Ja-deuk, the firm is committed to strengthening its capabilities, particularly in areas like bio deep tech, through strategic human resource expansion. Their approach involves active engagement and support to ensure the sustained growth and success of their portfolio companies.